A
AnBogen Therapeutics
AnBogen Therapeutics is a precision oncology company focusing on developing innovative therapies for cancer treatment
About AnBogen Therapeutics
AnBogen Therapeutics is a cutting-edge biotechnology startup focused on revolutionizing cancer treatment through precision oncology. Precision oncology is a medical approach that tailors treatment based on the individual genetic profile of each patient's cancer. The company is dedicated to bridging the gap between scientific research and clinical development, aiming to address unmet medical needs in cancer therapy.
AnBogen Therapeutics primarily serves cancer patients and healthcare providers, including hospitals and specialized cancer treatment centers. The company operates in the highly specialized and competitive biotechnology and pharmaceutical market, which is driven by innovation and regulatory approvals.
The business model of AnBogen Therapeutics revolves around drug discovery and development. They leverage their deep scientific knowledge and diverse expertise to create breakthrough therapies. The company makes money through a combination of funding from investors, grants, and partnerships with larger pharmaceutical companies. Additionally, revenue is generated from the successful commercialization of their developed therapies, which involves selling the drugs to healthcare providers and potentially licensing their technology to other companies.
Recently, AnBogen Therapeutics received approval from the U.S. FDA for a Phase Ib/II protocol amendment for their drug candidate ABT 101. This approval marks a significant milestone, allowing them to conduct clinical trials at multiple medical centers. Such advancements highlight their commitment to transforming cancer treatment and improving patient outcomes.
In summary, AnBogen Therapeutics is a pioneering company in the field of precision oncology, focused on developing innovative cancer therapies. They serve cancer patients and healthcare providers, operate in the biotech and pharmaceutical market, and generate revenue through drug development and commercialization.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Taipei, Taiwan
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 73.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2024 | $7.3M | $63M | KGI Venture Capital | ↗ |
| SERIES A✓Equity / VC | Feb 2024 | $13M | $50M | Maxpro · National Development Fund of Taiwan · Taian Venture Capital | ↗ |
Growth signals
Latest recorded traffic for AnBogen Therapeutics is 8.8K monthly website visits, up 131.6% over the last three months. AnBogen Therapeutics's team declined 5.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- MAMaxpro
- NTNational Development Fund of Taiwan
- TCTaian Venture Capital
KGI Venture Capital
Other known investors2 additional known investors
- NINational Health Research Institutes
CDIB Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AnBogen Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AnBogen Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.